MEDICLIN Aktiengesellschaft

DB:MED Stock Report

Market Cap: €116.9m

MEDICLIN Past Earnings Performance

Past criteria checks 0/6

MEDICLIN's earnings have been declining at an average annual rate of -3.1%, while the Healthcare industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 3.4% per year.

Key information

-3.1%

Earnings growth rate

-3.1%

EPS growth rate

Healthcare Industry Growth15.7%
Revenue growth rate3.4%
Return on equity-5.2%
Net Margin-1.5%
Next Earnings Update27 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MEDICLIN makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:MED Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24766-1170
30 Jun 24764-1570
31 Mar 24772-670
31 Dec 23762-1170
30 Sep 237522060
30 Jun 237341260
31 Mar 23723760
31 Dec 22719960
30 Sep 227131140
30 Jun 227161940
31 Mar 22701940
31 Dec 21684140
30 Sep 21662-930
30 Jun 21662-1430
31 Mar 21652-1630
31 Dec 20662-930
30 Sep 20674-140
30 Jun 20669-240
31 Mar 20680540
31 Dec 196801040
30 Sep 196652530
30 Jun 196654530
31 Mar 196617530
31 Dec 186518530
30 Sep 186390730
30 Jun 186354730
31 Mar 186245730
31 Dec 176154730
30 Sep 1760919510
30 Jun 1759914510
31 Mar 1759115510
31 Dec 1658317510
30 Sep 1658217510
30 Jun 1657019510
31 Mar 1656117510
31 Dec 1555517510
30 Sep 1555013510
30 Jun 1554612510
31 Mar 1554211510
31 Dec 145389510
30 Sep 145297500
30 Jun 145254500
31 Mar 145232500
31 Dec 13515-3500

Quality Earnings: MED is currently unprofitable.

Growing Profit Margin: MED is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MED is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.

Accelerating Growth: Unable to compare MED's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MED is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (40.5%).


Return on Equity

High ROE: MED has a negative Return on Equity (-5.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MEDICLIN Aktiengesellschaft is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Karl-Heinz ScheunemannLandesbank Baden-Wuerttemberg Equity and Fixed Income Research
Klaus SchloteSolventis Wertpapierhandelsbank GmbH
Nico LoechnerSolventis Wertpapierhandelsbank GmbH